Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 2017-09-05 (8 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: PERCY-EN-NORMANDIE (50410), Manche
PHARMACIE DU MONT ROBIN : revenue, balance sheet and financial ratios
PHARMACIE DU MONT ROBIN is a French company
founded 8 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in PERCY-EN-NORMANDIE (50410),
this company of category PME
shows in 2024 a revenue of 2.9 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DU MONT ROBIN (SIREN 831804067)
Indicator
2024
2023
2022
2021
2020
2019
2018
Revenue
2 874 965 €
N/C
2 656 334 €
N/C
N/C
N/C
N/C
Net income
126 083 €
110 501 €
162 846 €
150 249 €
122 016 €
141 475 €
739 €
EBITDA
183 006 €
N/C
237 233 €
N/C
N/C
N/C
N/C
Net margin
4.4%
N/C
6.1%
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, PHARMACIE DU MONT ROBIN achieves revenue of 2.9 M€. Revenue is growing positively over 7 years (CAGR: +4.0%). After deducting consumption (2.1 M€), gross margin stands at 792 k€, i.e. a rate of 28%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 183 k€, representing 6.4% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 126 k€, i.e. 4.4% of revenue. This profit can be retained or distributed to shareholders.
Revenue (2024)
?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production
2 874 965 €
Gross margin (2024)
?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed
791 946 €
EBITDA (2024)
?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity
183 006 €
EBIT (2024)
?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals
185 968 €
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
126 083 €
EBITDA margin (2024)
?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability 5-10% : Average < 5% : Low
6.4%
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 148%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 35%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 8.9 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 4.3% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
148.266%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
34.699%
Cash flow / Revenue (2024)
?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates
4.331%
Repayment capacity (2024)
?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent 3-5 years : Fair > 5 years : Warning
8.911
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE DU MONT ROBIN
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2021
2022
2023
2024
Debt ratio
3957.906
1000.819
638.276
395.142
257.932
199.816
148.266
Financial autonomy
2.192
8.05
12.227
17.142
24.296
28.803
34.699
Repayment capacity
None
None
None
None
8.439
None
8.911
Cash flow / Revenue
None%
None%
None%
None%
6.357%
None%
4.331%
Sector positioning
Debt ratio
148.272024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Average
In 2024, the debt ratio of PHARMACIE DU MONT ROBIN (148.27) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
34.7%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average+7 pts over 3 years
In 2024, the financial autonomy of PHARMACIE DU MONT ROBIN (34.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
8.91 years2024
2022
2024
Q1: 0.52 years
Med: 3.19 years
Q3: 7.6 years
Watch
In 2024, the repayment capacity of PHARMACIE DU MONT ROBIN (8.91) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 83.21. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 14.6x. Operating income very largely covers interest expenses: high safety margin.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
83.206
Interest coverage (2024)
?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable 1.5-3 : Acceptable < 1.5 : Risk
14.583
Liquidity indicators evolution PHARMACIE DU MONT ROBIN
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
129.351
134.467
154.993
125.584
112.911
93.659
83.206
Interest coverage
None
None
None
None
7.426
None
14.583
Sector positioning
Liquidity ratio
83.212024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Watch
In 2024, the liquidity ratio of PHARMACIE DU MONT ROBIN (83.21) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Interest coverage
14.58x2024
2022
2024
Q1: 0.0x
Med: 2.35x
Q3: 7.73x
Excellent
In 2024, the interest coverage of PHARMACIE DU MONT ROBIN (14.6x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 3 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 43 days. Excellent situation: suppliers finance 40 days of the operating cycle (retail model). Inventory turnover is 20 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 21 days of revenue, i.e. 165 k€ to permanently finance.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
165 397 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
3 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
43 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
20 j
WCR in days of revenue (2024)
?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management
21 j
WCR and payment terms evolution PHARMACIE DU MONT ROBIN
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2021
2022
2023
2024
Operating WCR
0 €
0 €
0 €
0 €
159 911 €
0 €
165 397 €
Inventory turnover (days)
0
0
0
0
21
0
20
Customer payment term (days)
114
125
143
126
5
136
3
Supplier payment term (days)
619
801
799
1306
44
1005
43
Positioning of PHARMACIE DU MONT ROBIN in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE DU MONT ROBIN is estimated at
1 748 744 €
(range 1 261 127€ - 2 535 638€).
With an EBITDA of 183 006€, the sector multiple of 9.2x is applied.
The price/revenue ratio is 0.64x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
1261k€1748k€2535k€
1 748 744 €Range: 1 261 127€ - 2 535 638€
NAF 5 année 2024
Valuation detail by method
Ajustez les pondérations selon votre analyse
EBITDA Multiple50%
183 006 €×9.2x
Estimation1 689 962 €
1 107 000€ - 2 627 543€
Revenue Multiple30%
2 874 965 €×0.64x
Estimation1 839 069 €
1 541 568€ - 2 317 303€
Net Income Multiple20%
126 083 €×14.0x
Estimation1 760 212 €
1 225 784€ - 2 633 378€
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DU MONT ROBIN with other companies in the same sector:
Frequently asked questions about PHARMACIE DU MONT ROBIN
What is the revenue of PHARMACIE DU MONT ROBIN ?
The revenue of PHARMACIE DU MONT ROBIN in 2024 is 2.9 M€.
Is PHARMACIE DU MONT ROBIN profitable?
Yes, PHARMACIE DU MONT ROBIN generated a net profit of 126 k€ in 2024.
Where is the headquarters of PHARMACIE DU MONT ROBIN ?
The headquarters of PHARMACIE DU MONT ROBIN is located in PERCY-EN-NORMANDIE (50410), in the department Manche.
Where to find the tax return of PHARMACIE DU MONT ROBIN ?
The tax return of PHARMACIE DU MONT ROBIN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DU MONT ROBIN operate?
PHARMACIE DU MONT ROBIN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart